Arun Menawat Net Worth

Arun Menawat biography

Dr. Arun Swarup Menawat Ph.D. serves as Independent Director of the Company. He is Chairman and CEO of Profound Medical Corp. (NASDAQ:PROF) (TXSV:PRN), a medical device company that is driving commercialization of real-time MRI-guided ablation for prostate diseases including cancer. Dr. Menawat has an accomplished history of executive leadership success in the healthcare industry. He was previously the Chairman, President and CEO of Novadaq Technologies Inc. (NASDAQ:NVDQ) (TXS:NDQ). Under his 13-year tenure at Novadaq, he transformed the company from a small private pre-commercial company into the leader in intraoperative imaging and was instrumental in signing strategic partnerships with companies including Intuitive Surgical, LifeCell, and KCI. He obtained a Ph.D. in Chemical (Bio) Engineering from the University of Maryland, while concurrently completing a fellowship in biomedical engineering at the U.S. National Institute of Health, and holds an Executive MBA from the J.L. Kellogg School of Management, Northwestern University. In 2014, Dr. Menawat was named the EY Ontario Entrepreneur of the Year in the health sciences category. Dr. Menawat’s strong executive experience with medical device companies provides the Board valuable guidance for product innovation, customer initiatives and operational matters.

What is the salary of Arun Menawat?

As the Independent Director of Stereotaxis, the total compensation of Arun Menawat at Stereotaxis is $240,300. There are no executives at Stereotaxis getting paid more.

How old is Arun Menawat?

Arun Menawat is 65, he's been the Independent Director of Stereotaxis since 2016. There are 2 older and 7 younger executives at Stereotaxis. The oldest executive at Stereotaxis, Inc. is Robert Messey, 74, who is the Independent Director.

What's Arun Menawat's mailing address?

Arun's mailing address filed with the SEC is 4320 Forest Park Ave, St. Louis, MO 63108, USA.

Insiders trading at Stereotaxis

Over the last 6 years, insiders at Stereotaxis have traded over $16,447,723 worth of Stereotaxis stock and bought 502,585 units worth $872,120 . The most active insiders traders include Joe E Kiani, Paul J Isaac und Myriam Curet. On average, Stereotaxis executives and independent directors trade stock every 39 days with the average trade being worth of $124,591. The most recent stock trade was executed by Paul J Isaac on 28 May 2024, trading 1,254 units of STXS stock currently worth $2,358.

What does Stereotaxis do?

Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.

Stereotaxis executives and stock owners

Stereotaxis executives and other stock owners filed with the SEC include:

• Ross Levin,
  Independent Director
• Robert Messey,
  Independent Director
• Arun Menawat,
  Independent Director
• Joseph Kiani,
  Independent Director
• David Benfer,
  Lead Independent Director
• Nathan Fischel,
  Director
• David Fischel,
  Chairman of the Board, Chief Executive Officer
• Kimberly R. Peery,
  Chief Financial Officer
• Kimberly Peery,
  Chief Financial Officer
• Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A., CFA, CPA,
  CEO & Chairman
• David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A., CFA, CPA,
  CEO & Chairman
• Guy Judkowski,
  Equity Portfolio Mang.
• Joe E Kiani,
  Director
• Paul J Isaac,
  Director
• Kevin M. Barry,
  Chief Legal Officer & Secretar
• Martin C Stammer,
  Chief Financial Officer
• Myriam Curet,
  Director